BPR1J-340
BPR1J-340 is a potent FLT3 inhibitor with an IC50 of ~25 nM. BPR1J-340 inhibits the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD+ acute myeloid leukemia (AML) cells. BPR1J-340 exhibits significant anti-tumor activities[1].
Product Specifications
CAS Number
1395051-72-5
UNSPSC
12352005
Target
Apoptosis; FLT3
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bpr1j-340.html
Smiles
O=C(NC1=NNC(C2=CC=C(CNC(NC3=NOC(CC)=C3)=O)C=C2)=C1)C4=CC=C(CN5CCN(C)CC5)C=C4
Molecular Formula
C29H34N8O3
Molecular Weight
542.63
References & Citations
[1]Wen-Hsing Lin, et al. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer. PLoS One. 2014 Jan 8;9 (1) :e83160.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470149-500 1x 500 µL
CD106 / VCAM1 (1.4C3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940031-100 1x 100 µL
Mucin 5AC (MUC5AC) (45M1), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880304-100 1x 100 µL
CD106 / VCAM1 (B-K9), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400748-100 1x 100 µL
CD5 (C5/473 + CD5/54/F6), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details